We use cookies to analyze the traffic on our website. The information is also shared with our partners in web analysis. By visiting our website, you agree to the use of cookies.

Gedea Biotech receives funding from Vinnova

Vinnova has granted Gedea Biotech's application for innovative startup companies. The applications were reviewed by external assessors and Gedea Biotech was one of the selected among over 650 applicants. Gedea Biotech develops a novel treatment of vaginal candida infections. In the project a prototype of the vaginal tablet will be formulated.
Read more

LU Holding invests in new treatment for common female problems

Three-quarters of all women suffer at some time of fungal infections in the genital area, which gives physical discomfort in the short term but is also likely to cause chronic problems. Now a research team at Lund University have found a naturally occurring substance, which in test tube studies have shown promising results against the right fungi. The university's holding company becomes a shareholder in a new company to bring the treatment to market
http://www.innovation.lu.se/article/lu-holding-investerar-i-ny-behandling-for-vanliga-kvinnobesvar
Article written by Rapidus: http://www.rapidus.se/lu-holding-investerar-i-innovation-mot-underlivsbesvar/
Article written by Näringsliv: http://www.naringsliv.se/tidningar/2017-1/life-science/life-science/innovation-facilitates-regional-growth/
kartaGedea Biotech AB
Medicon Village
Scheeletorget 1
223 81 Lund
Sweden
Annette Säfholm, CEO
annette.safholm@gedeabiotech.com
+46 (0) 708 - 91 86 81

Privacy Policy | Cookie Policy

Newsletter
Sign up for our newsletter